TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer
GlobeNewswire
*Company Announcement*
· *Full approval based on global Phase 3 study demonstrating overall survival benefit of TIVDAK..